Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

• Prif Awduron: Heriberto Bruzzoni-Giovanelli (Awdur), Habib Zouali (Awdur), Mourad Sahbatou (Awdur), Benjamin Maneglier (Awdur), Jean-Michel Cayuela (Awdur), Angelita Rebollo (Awdur), Gustavo H. Marin (Awdur), Daniela Geromin (Awdur), Carole Tomczak (Awdur), Antonio Alberdi (Awdur), Jean-Francois Deleuze (Awdur), Philippe Rousselot (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2024-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial...